Ebola Virus Vaccine Market Discussed in New Kuick Research Report Now Available at MarketPublishers.com

24 Oct 2014 • by Natalie Aster

LONDON - Discovered approximately 40 years ago, Ebola virus infection is most common in the Philippines as well as in the African region. Besides, it has been observed in Gabon, Sudan, Ivory Coast, and more.

However, there is still no standard treatment method used to treat the Ebola hemorrhagic fever. A licensed vaccine is also not available. That is why a supportive therapy is utilized.

The market for Ebola virus vaccines is an untapped market, with market players having big opportunities in terms of drug and vaccine development as well as introduction of measures related to control and prevention of spreading of the disease.

At present, there are only slightly over several dozens of Ebola vaccines in the clinical pipeline, with most of them being in a preclinical phase and many of them being in a research phase.

New in-demand market research study “Ebola Virus Vaccine Market & Pipeline Insight” elaborated by Kuick Research offers an insightful discussion of the market for Ebola vaccines.

The report provides a comprehensive overview of the market for Ebola virus infection including details on symptoms and diagnostics, causes of the infection, incidence, developments, besides covering a future scenario. The study reviews Ebola vaccine clinical trials (26 vaccines are mentioned); gives an insight into suspended as well as discontinued vaccine clinical trials. Moreover, the research report delves deep into the competitive landscape and offers data on such market participants as Fab Entech, Microbiotix, Crucell, Vaxart, among others.

Report Details:

Ebola Virus Vaccine Market & Pipeline Insight
Published: October, 2014
Pages: 80
Price: US$ 1,500.00

Other Vaccine Market Research Reports by Kuick Research Comprise:

More new cutting-edge research studies by the publisher can be found at Kuick Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970